ZIOP -to penny land & beyond!


Boston-based Ziopharm had planned to start testing Ad-RTS-hIL-12 in combination with veledimex in patients with recurrent glioblastoma by the end of last year. Ziopharm pushed back the target to the second half of 2018 when it learned it would take longer than expected to get the asset phase 3 ready. And it has now put the study on hold indefinitely.

Ziopharm is continuing to work to resolve the chemistry, manufacturing and control issue that forced it to delay the trial but it is shifting its clinical development focus to earlier-phase studies.

So… no clinical stage drugs moving forward. Shifting focus towards pre-clinical realm. Only has enough cash to last until 2q19.

ZIOP is moving backwards!

If only there were visible warning signs :thinking: